课题基金 / 基金详情

PRE TARGETED THERAPY USING THE NOVEL TACHYKININ (NK) REC

PRE TARGETED THERAPY USING THE NOVEL TACHYKININ (NK) REC
使用新型速激肽 (NK) REC 进行预靶向治疗
批准号:
6175066
负责人:
ROSALYN D BLUMENTHAL
金额:
$14.25万
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-07-01 至 2002-06-30

项目摘要

项目成果

ROSALYN D BLUMENTHAL的其他基金

相似基金

相关文献

中文摘要
翻译
描述:(申请人描述)
英文摘要
DESCRIPTION: (Applicant's Description) The long-term goal of these studies is to develop the use of peptide taraeting for the novel neuroendocrine neurokinin (NK) receptor system, which is constitutively overexpressed in breast cancer. Unlabeled substance P (SP), or analogues that selectively bind either NK-1 or NK-2 will be evaluated in vitro and in vivo. Auger-emitting radionuclides (e.g., IN-111) will be chelates to NK-Receptor targeting agents. Upon cell internalization of the carrier, In-111 is expected to have substantial radiotoxic effects, which are expected to translate into tumor growth controt effects in vivo. The studies have been subdivided into four hypothesis-driven aims. To achieve our stated goal, we will: (1) Use cultured breast cancer lines to establish an appropriate carrier of therapeutic agents to the NK-receptor system. The in vitro cytotoxicity of unconjugated SP agonist and antagonists (amino terminal fragment 6-11, CP-96,345) will be evaluated. Results will be compared with carriers containing radioindium. Binding affinity, internalization rate, and cell retention of the radionuclide will be established. (2) Determine whether the number of NK-1 and NK-2 binding sites is affected by exposure to cytokines (e.g., IFNa, IL-1, IL-6) or chemotherapy (e.g., taxol, doxorubicin). (3) Establish the biodistribution of NK-directed carriers in vivo in breast tumor xenografts. Uptake will be determined using whole tissue counting, whole animal imaging and microautoradiography of tissue sections. (4) Evaluate the therapeutic efficacy of SP-based carriers in a subcutaneous breast tumor model and a micrometastatic (intracardiac MDA-231) breast model. Potential GI and marrow toxicity will be assessed by monitoring body weight changes and white blood cell and platelet counts. Mice will also be monitored for possible neurotoxicity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Animal Studies
Chronobiological Principles to Maximize Efficacy of Alt*
PRE-CLINICAL COMBINATION CHEMO- AND RADIOANTIBODY THERAP
PRE-CLINICAL COMBINATION CHEMO/RADIOANTIBODY THERAPY
海外基金